Completed OBSERVATIONAL NCT00230269

The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers

Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Interventions PET-CT

Updated 6 times since 2017 Last updated: Jul 10, 2012 Started: May 31, 2003 Primary completion: Jun 30, 2006 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Head and Neck Cancer, this trial is completed. The trial is conducted by McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States